The prevalence of diabetes mellitus (DM) 
Introduction
According to The International Diabetes Federation, 425 million adults had diabetes in 2017, and the figure is expected to reach 629 million in 2045 (1) . Diabetes is diagnosed based on plasma glucose levels (either fasting plasma glucose ≥126 mg/dL or a 2-h plasma glucose value during a 75-g oral glucose tolerance test ≥200 mg/dL) or HbA1C ≥6.5% (2) . Glycated hemoglobin (HbA1c) is a form of hemoglobin produced in a non-enzymatic glycation pathway by hemoglobin exposure to plasma glucose. It reflects average blood glucose levels over the past 3 months and has a strong predictive value for diabetes complications (3, 4) . Monitoring HbA1c levels in patients with diabetes has been used as an indirect measure of average glycemia in several landmark studies of diabetes therapy (3, 4) . HbA1c testing is performed routinely in all patients with diabetes, along with other tools such as blood glucose monitoring, to optimize glycemic control. More recently, HbA1c measurement has been used for diagnosing prediabetes and diabetes (5) . Values ≥5.7% define prediabetes, while values ≥6.5% are characteristic of diabetes. POC or bedside testing is known as medical diagnostic testing that provides immediate re-sults using transportable instruments or test kits, performed by clinical staff without laboratory training. It also includes patient self-monitoring. Today, cheaper, faster and reliable POC testing instruments offer onsite results that reduce the time spent with classic laboratory measures (6) .
POC blood glucose monitoring test in diabetes management
Early detection and intervention is crucial in diabetes management. Lifestyle interventions reverse prediabetes and result in a reduction of diabetes incidence over more than ten years (7) . The benefits of achieving early glycemic control in the natural history of diabetes are important: every 1% reduction in HbA1c results in a 37% reduction in microvascular complications, a 43% reduction in amputations, a 21% reduction in death from peripheral vascular disease, and a 14% reduction in myocardial infarctions (4) . Diabetes and prediabetes may be screened and diagnosed based on the same tests: plasma glucose levels or HbA1c levels (2) . Glucose levels should be assessed in plasma separated immediately after blood collection. Glucose testing using glucose meters became a practice in the health care system around 1987 and it has been perfected from 1.2 kg instruments to light weight pocket-size devices. POC capillary blood glucose testing is currently used by health care providers and millions of diabetic patients. However, POC blood glucose testing is not recommended for diabetes diagnosis. Rather, it has been used for screening diabetes in lowand middle-income countries to decrease the disease burden (8) . Self-monitoring blood glucose (SMBG) is intended especially for patients that use multiple insulin injections per day or insulin pumps for diabetes treatment. Patients should monitor their glycemic value before every meal or snack, from time to time in postprandial state, during the night, when symptoms of hypoglycemia appear, and after they correct it, before driving, before and during exercising. Glycemic values can be determined up to 6-10 times per day (9) . The benefit of structured SMBG in the management of insulin treated patients is well-established (10) . Moreover, regular SMBG use in non-insulin treated patients also has a favorable impact on glycemic control (11, 12) . It is very important for SMBG to be integrated in an educational plan, in order to get benefit from it. One in 6 patients on oral medication who practise SMBG neither use the results, nor tell their doctor about them (13) . These findings demonstrate that glucose monitoring is a tool that helps to monitor diabetes status, facilitates management interventions (lifestyle changes, pharmacotherapy), but cannot be used without educational support. In hospital settings, the standard glucose determination remains the central laboratory value. However, POC blood glucose measurement is now the standard bedside glucose monitoring technique in a variety of clinical settings including acute and chronic care facilities, general hospital wards and intensive care units, physicians' offices, nursing homes and assisted living facilities (14) . In health care settings, patients have to be monitored before every meal or every 4-6 h if they do not receive nutrition. The frequency of blood glucose monitoring increases in patients on intravenous insulin infusion, ranging from every 30 min to every 2 h (9 (17) . BGMSs intended for prescription use in a hospital setting should be able to measure BG accurately down to 10 mg/ dl and up to 500 mg/dl, while those intended for use outside a hospital setting should be able to measure BG accurately down to 20 mg/dl (17). In a recent study, designed to evaluate the accuracy of 17 POC glucose meters, only 2 met the ISO 2013 criteria, and the mean absolute relative differences versus reference values ranged widely from 5.6% to 20.8% (18). Moreover, the price of the glucose strips did not correlate with the accuracy of the result (18). In another recent study, assessing the accuracy of the 18 most purchased personal blood glucose meters in USA, only 6 meters met the protocol-specified accuracy standard similar to current ISO and FDA standards, while the mean absolute relative differences versus reference values ranged from 5.3% to 15.5% (19) . The surveillance of post-marketing device performance should be taken into consideration in the future. Over time, analytical accuracy might no longer represent the initial accuracy of data that were submitted to the regulatory authorities. The performance of blood glucose meters diminishes over time (19) . However, the POC glucose meter technology is not always the cause of inaccuracy. Additional errors can come from: temperature, humidity, 
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POC Continuous Glucose Monitoring Systems (CGMS) in diabetes management
Hypo-and hyperglycemia are common complications encountered in clinical care settings despite time and effort dedicated to achieving and maintaining good glycemic control. A target glucose range of 140-180 mg/dl is recommended for the majority of hospitalized patients (21 A recent study reported benefits of using flash CGMS even in well-controlled T1DM by reducing the time spent in hypoglycemia compared to using SMBG (37) . Current guidelines have no specific recommendations for patients or for clinical setting use (38) . However, support in selecting appropriate system for specific patient has been issued recently (39) . Several factors such as: edema, shock state, use of vasoconstrictors affect peripheral perfusion in ICU patients and disturb the accuracy of capillary glucose measurements (40, 41) . Moreover, glucose measurement in ICU is performed intermittently with the risk of undetected hypoglycemia, and the workload for the ICU nursing staff is considerable (42) . In this respect, several studies have shown that CGMS may guide insulin treatment in critically ill patients similarly to intermittent POC measurements. The first-generation intravenous CGMS was evaluated in a multicenter observational study, in 100 critically-ill patients (43) . The authors concluded that it was easy to set up and use, attached to a peripheral venous catheter. Of the intravenous glucose monitoring measurements, 93% met the 2003 ISO Standards for accura- cy. Frequent and accurate POC blood glucose testing may improve the safety and efficacy of insulin therapy and blood glucose control in hospitalized patients (43) . A randomized controlled trial compared subcutaneous CGMS with frequent POC measurements in 156 critically ill patients (42) . Subcutaneous CGMS were found to be as safe and effective as intermittent POC testing and reduced nursing workload and daily costs (42) .
Another study compared subcutaneous and intravenous CGMS in 15 surgical patients, in operating rooms and intensive care units (3592 comparative samples). The intravenous CGMS STG-55 (Nikkiso, Tokyo, Japan) was defined as the standard device in the study, because it had previously shown acceptable accuracy compared to the blood gas analyzer (Pearson's correlation coefficient was 0.96) (44) . The study found that subcutaneous and intravenous CGMS were not highly correlated during either surgery or ICU stay. The subcutaneous CGMS iPro2 (Medtronic Japan, Tokyo, Japan) was limited in terms of utility because it could not display real-time blood glucose levels (45) . However, the authors did not deny the overall accuracy of subcutaneous CGMS, suggesting that blood glucose measurement during hemodynamic or fluid instability might be suitable for intravenous CGMS, while testing after stabilization might be suitable for the subcutaneous method (45) .
POC HbA1c assays in diabetes management
Diabetes and prediabetes may be screened and diagnosed based on the same tests: plasma glucose levels (discussed above) or HbA1c levels (2) . The HbA1c test has several advantages compared to plasma glucose criteria, including: fasting not required, better pre-analytical stability, and less variability during stress and illness. However, the lower sensitivity of HbA1c at the cut point of 6.5%, the greater cost and restricted availability of HbA1c testing in certain areas may offset the advantages. Moreover, it is important to take into consideration other factors that may impact hemoglobin glycation independently of glycaemia, including ethnicity, anemia, hemoglobinopathies, etc. HbA1c testing should be performed using a method that is certified by the National Glycohemoglobin Standardization Program (NGSP) (www.ngsp.org) and standardized to the Diabetes Control and Complications Trial (DCCT) assay (2) . Although POC instruments are available for HbA1c testing, there are concerns that limit their diagnostic application, such as: differences in their accuracy, testing performed by non-laboratory personnel, and lack of a proficiency testing program. Although some POC HbA1c assays may be NGSP certified, the use of POC assays for diagnostic purposes is not generally recommended (9) . Recently, some authorities approved the use of POC HbA1c testing in particular settings. The Australian Government approved the use of the HbA1c test for diagnosis of the Indigenous Australian population enrolled exclusively in the QAAMS POC Testing Program. This decision was based on the consistently high analytical quality of POC HbA1c testing in QAAMS, as evidenced by the results of continuing external quality assurance and quality control testing over the past 15 years (46) . DCA Vantage measured HbA1c values close to 6.5% both accurately and precisely. The authors argue that POC testing devices are suitable for the diagnosis of diabetes, and each individual POC device should be assessed independently when considering its suitability for diabetes diagnosis (46) . Conversely, POC HbA1c testing may be used for screening purposes. In a recent study, dental students were effective in screening patients in a dental school clinic for prediabetes or diabetes by assessing conventional risk factors for diabetes, obtaining finger stick blood samples and analyzing the results with HbA1c test kits (47) . Another recent study found that systematically screening adults (aged ≥45 years) for diabetes using a POC HbA1c test vs. standard practices greatly increases the chances for a screen to occur (P = 0.005). The authors concluded that POC HbA1c testing may be the most effective method to identify patients with unknown hyperglycemia (48) . HbA1c testing should be performed routinely in all diabetic patients during continuing care to assess glycemic control. The frequency of HbA1c testing depends on the achieved levels of HbA1c and their variability: at least two times a year in patients who meet treatment goals and every 3 months in patients who do not meet glycemic goals or whose therapy has changed (9) . The American Diabetes Association recommends optimal HbA1c targets for non-pregnant adults less than 7%, but each target must be individualized to the particular patient (9) . 
POC tests for detecting microalbuminuria
Chronic kidney disease (CKD) is a chronic complication characterized by increased albuminuria, decreased glomerular filtration rate, or other kidney damage. The final evolution of diabetic CKD is end-stage renal disease requiring dialysis or kidney transplantation. Screening for CKD in diabetic patients is done by measuring the albumin-creatinine ratio in spot urine collection. Measuring albumin alone, without simultaneously determining urinary creatinine, is susceptible to errors due to urine concentration variability. 
